

Date: 06th February, 2020

To,
The Manager,
Listing Department,
BSE Limited,
Phiroze Jeejeebhoy Tower,
Dalal Street, Mumbai 400 001
BSE Scrip Code: 540726

Dear Sir/Madam,


Sub: Earning Presentation- Q3FY20

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Earning Presentation for the Quarter ended on December 31, 2019.

Kindly take the above on record.

Yours faithfully,

For Trident Texofab Limited


Mehul N. Amareliya
Company Secretary & Compliance Officer
M. No. A54306



Encl. a/a

TRIDENT TEXOFAB LIMITED

Q3FY20 Earnings Presentation

BSE: TTFL

Bloomberg: TTFLTD:IN

February 2020



COMPANY OVERVIEW



- Incorporated in 2008, Trident Texofab Limited is a composite textile manufacturing and trading company dealing in various finished and semi-finished products such as home furnishing, garments, suiting and shirting.
- TTFL has recently started manufacturing polyester-blend fabrics as a business division in 2018. TTFL manufactures right from grey fabrics to finished garments.
- TTFL got listed on BSE SME on October 5, 2017 with an IPO of 3.53 Crores.






First Generation Promoters



500 Lakh meters
Annual Manufacturing Capacity




BSE SME Listed


COMPANY SNAPSHOT



100 Team Strength




Composite
Manufacturing Unit



Shift from Pure trading to
composite manufacturing
unit



Wide portfolio of finished
and semi-finished products



Retail Clientele: TCNS,
Libas

BUSINESS DIVISION



Manufacturing

- Commenced in 2018, contributed 24.90% of revenue in FY2019.
- To drive incremental growth at TTFL in the years to come.
- Contributed **25.93%** of Revenue from operations in **Q3FY20** as compared to 22.74% in Q2FY20.

Trading

- Majority business contributor since inception. Contributed 75.10% of sale in FY2019.
- Will maintain similar level of operations as witnessed in the past 5 years.
- Contributed **74.07%** of Revenue from operations in **Q3FY20** as compared to 77.26% in Q2FY20.



PRODUCT PORTFOLIO



MANUFACTURING

Finished Products

- Kurtis
- Tunics
- Nighty
- Suiting
- Gowns

Semi-Finished Products

- Grey Fabrics
- Job Work for Digital Printing
- Value Added Products: Embroidery, etc.



PRODUCT PORTFOLIO



TRADING

Finished Products

- Curtains & Shower Curtains
- Cushion Covers
- Quilt Sheets
- Bed Sheets
- All Overs



FINANCIAL SUMMARY



Profit & Loss Summary (Quarterly)

(In Lakhs)

PARTICULARS	Q3FY20 (Unaudited)	Q2FY20 (Unaudited)	Q3FY19 (Unaudited)	Y-o-Y % (change)
Revenue from operations	1992.15	2237.86	1674.07	19.00%
Total Income	1999.34	2245.36	1682.59	18.83%
Total Operating Expenses	1847.38	2111.98	1614.26	14.44%
EBIDTA (Excluding OI)	144.77	125.88	59.81	142.05%
EBIDTA (Excluding OI) %	7.3%	5.6%	3.6%	103.40%
Interest Cost	102.33	80.83	29.33	248.89%
Depreciation & Amortization	20.73	20.69	12.89	60.82%
Profit Before Taxes	25.10	24.36	24.80	1.21%
Profit After Taxes	23.18	13.70	24.80	-6.53%

FINANCIAL SUMMARY



Profit & Loss Summary

(In Lakhs)

PARTICULARS	FY19	FY18	FY17	FY16	FY15
Revenue from operations	8689.74	8546.24	7594.76	6597.91	6255.87
Total Income	8736.54	8594.15	7619.19	6603.29	6265.38
Total Operating Expenses	8450.88	8400.93	7480.00	6499.34	6137.96
EBIDTA (Excluding OI)	238.86	145.31	114.76	98.57	117.91
EBIDTA (Excluding OI) %	2.7%	1.7%	1.5%	1.5%	1.9%
Interest Cost	86.47	76.96	68.23	60.45	80.34
Depreciation & Amortization	30.39	12.59	13.01	13.50	19.15
Profit Before Taxes	168.97	103.67	56.37	9.32	24.92
Profit After Taxes	127.42	75.00	34.12	5.87	18.02

FINANCIAL SUMMARY



Balance Sheet Summary


(In Lakhs)

PARTICULARS	FY19	FY18	FY17	FY16	FY15
Shareholders Fund	1099.54	826.36	380.39	346.28	343.41
Non-Current Liabilities	926.19	419.11	370.53	52.35	119.59
Current Liabilities	2882.75	3248.20	1698.63	3400.06	2378.84
Total	4908.47	4493.67	2449.55	3798.69	2841.84
Non-Current Assets	1133.57	470.47	232.64	178.48	176.24
Current Assets	3774.91	4023.20	2216.91	3620.19	2665.60
Total	4908.47	4493.67	2449.55	3798.67	2841.84


FINANCIAL RATIOS




Gross Profit %




EBIDTA % (Excluding O.I. & Exceptional Items)



Debt to Equity



Interest Coverage



MANAGEMENT COMMENTARY




Result Discussion

- The company has recorded a commendable growth in revenue from operations despite adverse macro-economic conditions and challenging business environment. The company grew its revenue from operations by 19.00% on a y-o-y basis, i.e. from 1674.07 Lakhs in Q3FY19 to 1992.15 Lakhs in Q3FY20.
- The company is on-track towards accomplishing its objective of 'Shifting Gears' from being a pure trading player up till 2018, to becoming a semi-composite manufacturing and trading company. Higher revenue contribution from manufacturing activities has led to a gradual increase in the operating profitability of the company.
- The company has achieved an all-time high EBITDA% (excluding OI and EI) of 7.3% in Q3FY20 as compared to 3.6% in Q3FY19. However, higher interest cost and depreciation, on account freshly commenced CAPEX, have led to suppressed net profitability.

- The company reported a PAT of 23.18 Lakhs in Q3FY20, a decrease of 6.53%, as compared to 24.80 Lakhs in Q3FY19.

Budget 2020

- Finance Minister Nirmala Sitharaman on Saturday proposed National Technical Textile Mission with an outlay of Rs 1,480 crore over four years to cut down imports. India imports a significant quantity of technical textiles worth \$16 billion every year. To reverse this trend and to position India as a global leader in technical textiles, a National Technical Textiles Mission is proposed.
- She also announced the abolition of anti-dumping duty on PTA, a key raw material for synthetic textiles. The removal of anti-dumping duty on PTA would make the import of PTA cheaper for the man-made fabric industry.



Ms. Bhumika Punjabi
(Corporate Governance Manager)

Trident Texofab Limited

bhumika@tridenttexofab.com

0261 – 2451274/2451284



CONTACT US



DISCLAIMER

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be “forward looking statements” based on the currently held beliefs and assumptions of the management of Trident Texofab Limited (“Company” or “Trident”), which are expressed in good faith and in their opinion reasonable, including those relating to the Company’s general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company’s business, its competitive environment and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments. This presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any securities in any jurisdiction. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. This presentation may not be copied or disseminated, in whole or in part, and in any manner.